Recent developments include clinical progress on PTSD drug SPC-15, strategic partnerships, capital raising activities, and treasury management initiatives.

• Silo Pharma announced a $1 million share buyback program in February 2026 [N1].
• The company plans to submit an IND application for its PTSD drug SPC-15 with a potential Phase 1 trial in 2026 [N3].
• Silo Pharma and Hoth Therapeutics launched a joint venture to commercialize a VA-invented obesity drug in June 2025 [N4][N5].
• Silo Pharma received a Notice of Allowance for a patent strengthening SPC-15 treatment for PTSD in June 2025 [N6].
• The company approved a $1 million Bitcoin purchase as a treasury reserve asset in June 2025 [N7].
• Silo Pharma partnered with Resyca BV for a drug-device study aimed at PTSD treatment with SPC-15 in May 2025 [N8].
• The company completed a public offering raising approximately $2 million in May 2025 [N8].

Silo Pharma’s development of novel therapeutics targeting PTSD, fibromyalgia, and CNS diseases addresses significant unmet medical needs. The company’s progress in clinical development, including plans for an IND submission and Phase 1 trial for SPC-15, and receipt of patent allowances, supports its product pipeline. Strategic partnerships, such as the joint venture with Hoth Therapeutics for obesity treatment, expand its commercial potential. The recent public offering and share buyback program demonstrate active capital management. Additionally, the company’s diversification into digital assets may provide alternative liquidity sources. These factors collectively contribute to potential growth in a nascent psychedelics-based medicine market.

Silo Pharma operates in a highly regulated environment with product candidates containing controlled substances subject to stringent DEA and FDA controls, which may delay or prevent regulatory approval and commercialization. The company has a limited operating history and has not achieved profitability, reporting a net loss and minimal revenue for the latest fiscal year. It faces Nasdaq listing compliance risks due to minimum bid price deficiencies, which could impact liquidity and financing ability. The emerging psychedelics market is subject to public controversy, regulatory uncertainty, and evolving legal frameworks, which may adversely affect market acceptance. Additionally, the company’s digital asset holdings expose it to market volatility, liquidity risks, and cybersecurity threats. These factors contribute to significant operational and financial risks.

Silo Pharma’s moat is primarily based on its proprietary development of novel therapeutics involving controlled substances such as psilocybin and ketamine, which are subject to complex regulatory approval processes that create high barriers to entry. The company has secured patent allowances strengthening its PTSD treatment SPC-15 and has formed strategic partnerships and joint ventures to commercialize its products, including a collaboration with Hoth Therapeutics for an obesity drug. Its focus on underserved medical conditions and the emerging psychedelics market provides a niche positioning. However, the company faces significant regulatory, clinical, and market acceptance risks, and its relatively early-stage development status limits established competitive advantages.

• Regulatory Risks Related to Controlled Substances: Silo Pharma’s product candidates contain controlled substances such as psilocybin and ketamine, which are classified under DEA schedules with strict manufacturing, distribution, and clinical trial regulations. Rescheduling and FDA approval processes are complex and may introduce delays or unfavorable outcomes, impacting commercialization potential [S1].
• Financial and Capital Risks: The company has a history of net losses and limited revenue, requiring additional financing to continue operations. Failure to raise capital or comply with Nasdaq listing requirements could adversely affect liquidity, stock price, and ability to operate [S1,S2].
• Market and Industry Risks: The psychedelics industry is nascent and subject to public controversy, evolving regulatory frameworks, and uncertain market acceptance. Negative publicity or political opposition could delay approvals or limit market penetration [S1].
• Digital Asset and Cryptocurrency Risks: Silo Pharma’s treasury policy includes digital asset investments, which are subject to significant volatility, liquidity constraints, regulatory uncertainty, and cybersecurity risks. Loss or inability to liquidate digital assets could negatively impact financial condition [S1,S2].
• Operational and Cybersecurity Risks: The company relies on information technology systems vulnerable to cyber-attacks, data breaches, and service interruptions, which could disrupt operations and compromise confidential information [S1].
• Management and Personnel Risks: The company’s success depends on retaining key executives and qualified personnel. Loss of key management or inability to attract talent could adversely affect business operations [S1].

• Silo Pharma, Inc. is a biopharmaceutical company focused on developing novel therapeutics addressing underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases.
• The company has recently expanded its operations to include a treasury policy allocating resources to digital assets, including a $1 million Bitcoin purchase approved as a treasury reserve asset.
• Silo Pharma is developing product candidates containing controlled substances such as psilocybin and ketamine, which are subject to strict regulatory controls under the DEA and FDA in the United States.
• The company’s product candidate SPC-15 is aimed at treating PTSD and has received a Notice of Allowance for a patent strengthening this treatment.
• Silo Pharma has partnered with Resyca BV for a drug-device study of SPC-15 targeting PTSD treatment.
• The company plans to submit an IND application for SPC-15 with a potential Phase 1 trial in 2026.
• Silo Pharma and Hoth Therapeutics have formed a joint venture to commercialize a VA-invented obesity drug.
• The company completed a public offering raising approximately $2 million in May 2025.
• Silo Pharma announced a $1 million share buyback program in February 2026.
• The company reported revenue of $72,102 and a net loss of $4,227,698 for the fiscal year ended December 31, 2025.
• Basic and diluted earnings per share were both -$0.50 for the fiscal year ended December 31, 2025.
• As of December 31, 2025, Silo Pharma had cash and cash equivalents of approximately $4.75 million and short-term investments of about $2.11 million.
• The company’s current assets were $7.39 million and current liabilities were $650,183 as of December 31, 2025, resulting in a current ratio of 11.36 and a cash ratio of 10.55.
• Silo Pharma is listed on the Nasdaq Capital Market but has received notifications for non-compliance with the minimum bid price requirement, with a compliance deadline extended to June 22, 2026.
• The company faces regulatory risks related to the scheduling and approval of controlled substances, including potential delays and costs associated with DEA and FDA regulations.
• Silo Pharma’s business and financial results are subject to risks including the need for additional financing, regulatory compliance, cybersecurity threats, and market acceptance of psychedelic-based therapies.
• The company holds options and warrants outstanding that may dilute existing shareholders.
• Silo Pharma is not currently an investment company under the Investment Company Act of 1940 despite its digital asset holdings, and it manages regulatory risks related to digital assets and cryptocurrencies.
• The company’s digital asset holdings are subject to risks including market volatility, liquidity constraints, regulatory uncertainty, and cybersecurity threats.
• Silo Pharma’s management team, including CEO Eric Weisblum, is critical to its operations, and retention of key personnel is a risk factor.